@HealthReadiness
info@healthsystemreadiness.com
  • All
  • Events
  • News
  • Opinion
  • Radioligand Therapy
    • News
    Radiopharmaceuticals Patient Advocacy Toolkit launched

    Radiopharmaceuticals Patient Advocacy Toolkit launched

    The Health Policy Partnership has launched an online toolkit that collates information on what radiopharmaceuticals are and how they become available to patients.
    Read More
    News
    ‘Readiness in reality: activities supporting the future of radioligand therapy’ – register now

    ‘Readiness in reality: activities supporting the future of radioligand therapy’ – register now

    HPP warmly invites you to 'Readiness in reality: activities supporting the future of radioligand therapy'. This free online event will take place on 17 November 2022.
    Read More
    News
    Introducing the UK Molecular Radiotherapy Consortium

    Introducing the UK Molecular Radiotherapy Consortium

    The UK Molecular Radiotherapy Consortium is an alliance of clinicians and patient advocates formed to support equitable access to evidence-based theranostic MRT across the UK.
    Read More
    Opinion
    How consistent terminology can aid integration of radioligand therapy

    How consistent terminology can aid integration of radioligand therapy

    Inconsistent use of terminology presents challenges to building awareness of radioligand therapy and appropriately integrating it into care.
    Read More
    News
    Call to share experiences of integrating radioligand therapy into care

    Call to share experiences of integrating radioligand therapy into care

    The Health Policy Partnership wants to better understand what actions and initiatives have taken place to improve the delivery of radioligand therapy.
    Read More
    Opinion
    World Theranostics Day 2022: what are theranostics and how can we use them?

    World Theranostics Day 2022: what are theranostics and how can we use them?

    On World Theranostics Day 2022, HPP explores the ongoing innovation and advancement in the field of theranostics.
    Read More
    Opinion
    We need continued research to ensure wider access to innovative therapies as soon as they are approved

    We need continued research to ensure wider access to innovative therapies as soon as they are approved

    In this guest blog, Dr Erik Briers emphasises the need for continued research and planning to make radioligand therapy a more viable treatment option.
    Read More
    News
    SPARC-Europe highlights patient experience of radioligand therapy in new video

    SPARC-Europe highlights patient experience of radioligand therapy in new video

    SPARC-Europe has released a video of patient testimonies to raise awareness of the benefits of radioligand therapy and outline some of the challenges to access.
    Read More
    News
    New templates to aid application of the Radioligand Therapy Readiness Assessment Framework

    New templates to aid application of the Radioligand Therapy Readiness Assessment Framework

    The Health Policy Partnership has published a series of templates to support independent applications of the Radioligand Therapy Readiness Assessment Framework.
    Read More
    Events
    Conference session considers what is needed for radioligand therapy in prostate cancer

    Conference session considers what is needed for radioligand therapy in prostate cancer

    The Health Policy Partnership held a session on multidisciplinary collaboration for health system readiness at the 13th European Multidisciplinary Congress on Urological Cancers.
    Read More
    News
    ASH 2021 poster focuses on uptake of radioimmunotherapy for lymphoma

    ASH 2021 poster focuses on uptake of radioimmunotherapy for lymphoma

    The Health Policy Partnership has published a poster at the 63rd annual meeting of the American Society of Hematology (ASH).
    Read More
    Opinion
    New cancer therapies: how workforce capacity impacts treatment implementation

    New cancer therapies: how workforce capacity impacts treatment implementation

    For his guest blog, Dr Martin Rolles explores how lack of workforce planning and specialist training can be a barrier to implementing new cancer therapies.
    Read More